Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# InSphero

## Sitemaps
[XML Sitemap](https://insphero.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Opinion Letter on In Vitro to In Vivo Extrapolation Applied to Drug Safety Assessment](https://insphero.com/opinion-piece-bruno-filippi-ivive/): The center of gravity in drug development is shifting from animal-first to human-relevant by design. The landscape of preclinical therapeutic development is undergoing a fundamental transformation, driven by an unprecedented, coordinated regulatory and financial push from the United States government. The convergence of recent legislation, strategic regulatory roadmaps, and historic federal funding signals a non-negotiable shift toward human-centric testing and the imminent end of the era of mandatory animal experimentation.
- [InSphero Accelerates Global Growth and US Expansion with Acquisition of PhenoVista Biosciences](https://insphero.com/insphero-us-expansion-with-phenovista/): InSphero has acquired California-based PhenoVista Biosciences to expand its US presence and strengthen advanced imaging and phenotypic analysis capabilities for predictive drug discovery and safety testing.
- [Two Teams, One Goal: How the 3D InSight™ DIGIT Platform came to life](https://insphero.com/digit-platform-insphero-doppl-integration-story/): The center of gravity in drug development is shifting from animal-first to human-relevant by design. The landscape of preclinical therapeutic development is undergoing a fundamental transformation, driven by an unprecedented, coordinated regulatory and financial push from the United States government. The convergence of recent legislation, strategic regulatory roadmaps, and historic federal funding signals a non-negotiable shift toward human-centric testing and the imminent end of the era of mandatory animal experimentation.
- [Building the Future of Safety Pharmacology – Our Vision for comprehensive, human relevant drug testing](https://insphero.com/advancing-safety-pharmacology-with-human-relevant-testing/): The center of gravity in drug development is shifting from animal-first to human-relevant by design. The landscape of preclinical therapeutic development is undergoing a fundamental transformation, driven by an unprecedented, coordinated regulatory and financial push from the United States government. The convergence of recent legislation, strategic regulatory roadmaps, and historic federal funding signals a non-negotiable shift toward human-centric testing and the imminent end of the era of mandatory animal experimentation.
- [InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment ](https://insphero.com/insphero-launches-3d-insight-gi-toxicity-screening-platform/): InSphero AG has signed a definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in organoid technologies, including the Sun Bioscience Gri3D® platform. The deal strengthens InSphero’s position as the most comprehensive provider of advanced 3D in vitro models for drug discovery and safety testing.
- [InSphero and PharmaNest Form a Partnership to Advance Translational Fibrosis Research ](https://insphero.com/insphero-and-pharmanest-partner-for-fibrosis-research/): InSphero has entered a strategic partnership with PharmaNest Inc to advance the translational assessment of fibrosis in human-relevant 3D in vitro models. By combining advanced 3D liver spheroids with high-resolution, AI-enabled digital pathology, the collaboration aims to enable quantitative, phenotype-resolved analysis of fibrotic remodeling and improve the prediction of therapeutic efficacy in complex fibrotic diseases.
- [Industry Leaders Announce World’s First Microphysiological Systems Industry Association (IAMPS) ](https://insphero.com/iamps-insphero-joins-as-a-founding-member/): European microphysiological systems (MPS) industry leaders are announcing today the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world's first industry association dedicated to represent MPS providers.
- [The NIH Standardized Organoid Modeling (SOM) Institute: Standardization, Regulatory Readiness, and the Next Phase of Human-Relevant Biology ](https://insphero.com/nih-som-standardizing-organoids/): The center of gravity in drug development is shifting from animal-first to human-relevant by design. The landscape of preclinical therapeutic development is undergoing a fundamental transformation, driven by an unprecedented, coordinated regulatory and financial push from the United States government. The convergence of recent legislation, strategic regulatory roadmaps, and historic federal funding signals a non-negotiable shift toward human-centric testing and the imminent end of the era of mandatory animal experimentation.
- [Redefining Drug Development: How FDA’s Draft Guidance Refines the Regulatory Framework for Non-Human Primate Use](https://insphero.com/human-relevant-safety-science/): The center of gravity in drug development is shifting from animal-first to human-relevant by design. The landscape of preclinical therapeutic development is undergoing a fundamental transformation, driven by an unprecedented, coordinated regulatory and financial push from the United States government. The convergence of recent legislation, strategic regulatory roadmaps, and historic federal funding signals a non-negotiable shift toward human-centric testing and the imminent end of the era of mandatory animal experimentation.
- [InSphero Expands 3D Cell Model Leadership with Acquisition of DOPPL SA and Sun Bioscience Gri3D® Technology](https://insphero.com/insphero-acquires-doppl-3d-cell-models/): InSphero AG has signed a definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in organoid technologies, including the Sun Bioscience Gri3D® platform. The deal strengthens InSphero’s position as the most comprehensive provider of advanced 3D in vitro models for drug discovery and safety testing.
- [The Human-Centric Mandate: Why NIH and FDA’s Coordinated Push Makes Standardized 3D Models the New Default ](https://insphero.com/human-centric-drug-testing/): The center of gravity in drug development is shifting from animal-first to human-relevant by design. The landscape of preclinical therapeutic development is undergoing a fundamental transformation, driven by an unprecedented, coordinated regulatory and financial push from the United States government. The convergence of recent legislation, strategic regulatory roadmaps, and historic federal funding signals a non-negotiable shift toward human-centric testing and the imminent end of the era of mandatory animal experimentation.
- [Physicians Committee for Responsible Medicine and InSphero Announce Winners of the HUMAIN Award](https://insphero.com/humain-award-2025/): The Physicians Committee and InSphero Launch Award Program to Accelerate Adoption of Human In Vitro Models.
- [The Nobel Prize in Physiology or Medicine 2025: A Celebration of Immune Balance and a Reminder of Why We Build Immune-Competent 3D Models](https://insphero.com/nobel2025-celebrating-discoveries-in-immune-tolerance/): The 2025 Nobel Prize in Physiology or Medicine celebrates the discovery of regulatory T cells (Tregs) and their central role in maintaining immune tolerance, a breakthrough that reshaped modern immunology. At InSphero, this milestone reinforces our mission to integrate immune context into 3D in vitro models. By developing immune-competent systems that capture the balance between activation and suppression, we aim to better reflect human biology in disease research, oncology, and safety testing.
- [InSphero Appoints Werner Lanthaler to Its Board of Directors](https://insphero.com/insphero-appoints-werner-lanthaler-to-its-board-of-directors/): InSphero appoints former Evotec CEO Dr. Werner Lanthaler to its Board of Directors, strengthening its mission to scale reliable 3D in vitro drug testing solutions.
- [Brenus Pharma and InSphero have developed 3D tumor spheroids mimicking in vivo human colorectal cancer conditions and confirming STC-1010’s efficacy](https://insphero.com/brenus-pharma-and-insphero-collaboration/): InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.
- [InSphero and Hesperos Announce Strategic Collaboration to Offer End-to-End Solutions in Drug Discovery and Toxicology](https://insphero.com/insphero-hesperos-partnership-mps/): InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.
- [InSphero Expands 3D Microtissue Portfolio Through Strategic Agreement with Tessara Therapeutics](https://insphero.com/insphero-tessara-therapeutics-agreement/): InSphero has entered into a distribution agreement with Tessara Therapeutics, an Australian biotech company known for its advanced neuronal microtissue technology. This agreement further strengthens our portfolio of physiologically relevant 3D models and enables us to offer best-in-class neuronal assays to our global customer base.
- [New FDA Roadmap charts a path to reducing animal testing: Progress, promise, and what’s still missing](https://insphero.com/new-fda-roadmap-charts-a-path-to-reducing-animal-testing-progress-promise-and-whats-still-missing/): The FDA’s new roadmap to phase out animal use in preclinical safety testing marks a transformative step toward human-relevant science. By endorsing New Approach Methodologies (NAMs) such as spheroids, organoids, organ-on-chip platforms, and AI-based modeling, the roadmap paves the way for more predictive and ethical drug development. In this post, we highlight what makes this milestone worth celebrating and where stronger focus and collaboration are still needed to turn vision into practice.
- [Diversity in Preclinical Research is Science not Politics: A Key to Safer and More Effective Drug Development](https://insphero.com/diversity-in-preclinical-research/): In recent years, “diversity” has often been discussed in societal and political contexts, sometimes creating misconceptions about its role in science and technology. However, within the field of preclinical drug development, patient diversity is not a political buzzword - it is a scientific imperative.
- [InSphero CSO Dr. Madhu Nag Appointed to SLAS Board of Directors](https://insphero.com/insphero-cso-madhu-nag-slas-board-of-directors/): InSphero is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.
- [InSphero Awarded Major EU Grant to Address Diversity in 3D <i>In Vitro</i> Testing](https://insphero.com/unlooc-insphero-eu-grant-3dinvitro-testing/): InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.
- [Alternative Animal Models: Advancing the 3Rs in Preclinical Drug Testing](https://insphero.com/alternative-animal-models-advancing-3rs-in-testing/): Animal Microphysiological Systems (MPS) provide ethical, in vitro alternatives to animal testing, advancing the 3Rs—Replacement, Reduction, and Refinement. InSphero’s XSpecies Consortium demonstrates how liver MPS can predict species-specific toxicities, bridging the gap between animal and human responses to support drug preclinical safety assessment.
- [InSphero Partners with Chayon to Bring Advanced 3D In Vitro Technologies to South Korean Researchers](https://insphero.com/insphero-chayon-3dtech-southkorea/): InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. FDA's NCTR have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues.
- [InSphero and FDA’s NCTR Publish the Largest Benchmarking Study Demonstrating Early Detection of Liver Toxicity Using 3D Liver Microtissues](https://insphero.com/insphero-fda-liver-toxicity-study-3d-microtissues/): InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. FDA's NCTR have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues.
- [The FDA Modernization Act 3.0: Paving the Way for a New Era in Drug Development or a Gentle Nudge?](https://insphero.com/fda-modernization-act-3-0-drug-development/): In a significant step toward making drug development more patient-centric, the FDA Modernization Act 3.0 was introduced as a major piece of forward-looking legislation in February 2024. For stakeholders across the biopharmaceutical industry, including companies like InSphero that specialize in complex in vitro models, this legislation presents both promising opportunities and new challenges. Will it change things?

## Pages
- [High Content Imaging (HCI)](https://insphero.com/technology/high-content-imaging-hci/): High-content imaging (HCI) in spheroids is a powerful, histology-like approach that enables detailed analysis of proteins, cells, and tissue architecture within physiologically relevant 3D microtissues. When applied to InSphero’s 3D InSight™ Microtissue Models, HCI captures complex biological responses that closely mirror the in vivo tissue environment. 
- [3D InSight ™ Drug-Induced Gastrointestinal Toxicity Assessment Schedule](https://insphero.com/3d-insight-digit-service-schedule/): Accelerate confident early decision-making with our standardized gastrointestinal cytotoxicity and organoid swelling assay for fast, reliable, and predictive assessment of drug-induced gastrointestinal toxicity (DIGIT) early in your drug discovery pipeline.
- [Ready-to-use Spheroids & 3D cell culture kits](https://insphero.com/ready-to-use-spheroids/): Add human relevance to therapeutic development and accelerate go/no-go confident decisions by integrating ready-to-use spheroids - new approach methods (NAMs) - into your drug discovery pipeline.
- [Gri3D technology page](https://insphero.com/technology/gri3d-hydrogel-microcavity-technology/): Gri3D® Technology enables the precise and reproducible formation of uniform organoids within ready-to-use hydrogel microplates, bringing true 3D biology to everyday research workflows.
- [Ethics Policy](https://insphero.com/ethics-policy/): This Ethics Policy applies to InSphero AG, 8952 Schlieren, Switzerland, and to InSphero Inc., Brunswick, ME 04011, USA, and underlies the business of InSphero in terms of the development and production of biological products based on animal and human cells in compliance with applicable regulatory standards and ethical principles.
- [3D InSight™ DILI Service Schedule](https://insphero.com/3d-insight-dili-service-schedule/): Streamline your decision-making with our standardized, high-throughput cytotoxicity DILI assay, available with human-derived and species-specific liver models. We offer regular 3D in vitro human and animal DILI testing, evaluating 7 concentrations of your compound in 4 biological replicates over 7, 14 and up to 28 days.
- [RealBrain® Technology](https://insphero.com/technology/realbrain-technology/): To address this challenge, we have joined forces with Tessara Therapeutics, the innovator behind RealBrain® technology.
- [Blog](https://insphero.com/blog/): InSphero scientists share practical insights on 3D cell culture, organ-on-chip, DILI/MASH modeling, and islet biology: methods, case studies, and tips for reproducible results.
- [RNA Sequencing in Spheroids](https://insphero.com/technology/rna-sequencing-in-spheroids/): RNA sequencing in spheroids is a cutting-edge technique used to study gene expression in three-dimensional cellular structures that closely mimic the in vivo environment of tissues. Unlike traditional 2D cultures, 3D spheroids provide a more physiologically relevant context, capturing cell-cell and cell-matrix interactions.
- [Akura™ Organ-on-Chip Technology](https://insphero.com/technology/akura-organ-on-chip-technology/): Akura™ Organ-on-Chip technology is built on pre-formed spheroid and organoid tissue models and is compatible with InSphero’s complete portfolio of 3D InSight™ Human Microtissues. The approach provides experimental continuity between single- and multi-organ testing applications, enabling seamless integration and a step-by-step increase in biological complexity.
- [Akura License Policy](https://insphero.com/akura-license/): This License Agreement (the „License Agreement“) is a legal agreement between the end user („End User“) and InSphero AG or its subsidiaries („InSphero“) to use the Akura™ 96 Spheroid Microplate, Akura™ 384 Spheroid Microplate, Akura™ 384 ImagePro and Akura™ PLUS Hanging Drop System  and Gri3D® Hydrogel Microcavity Plates („Plates“) covered by patents owned or controlled by InSphero which are provided to you.
- [Akura™ Microplate Technology](https://insphero.com/technology/akura-microplate-technology/): The unique features of the microplate technology enable scientists to perform all steps of 3D biological assays: from spheroid formation, long-term experimental protocols, to complex multi-parametric analysis in a single plate. Simple and robust handling is guaranteed for manual pipetting steps as well as when implemented in high-throughput screens. 
- [Medical Disclaimer](https://insphero.com/medical-disclaimer/): Medical Disclaimer: You understand that any information and content, such as text, graphics, and images, found within our Website is for general educational, entertainment, and informational purposes only. You understand that such information is not intended nor otherwise implied to be medical advice or a substitute for medical advice, diagnosis, or treatment.
- [Terms & Conditions](https://insphero.com/terms-and-conditions/): These general terms and conditions of sale of Products and Services (GTCS) shall apply to all Agreements concluded between InSphero and the Customer (each as defined below); (referred to herein each, as a Party, and together as the Parties) and override any conflicting or additional terms and conditions contained in any purchase order or similar documents provided by the Customer to InSphero concerning the purchase or supply of Products or Services. Omission by InSphero to explicitly object or reject terms and conditions provided by the Customer will in no event be construed as an acceptance of any of these terms and conditions of the Customer by InSphero.
- [Privacy Policy](https://insphero.com/privacy-policy/): Privacy Policy – Effective Date: January 1, 2023
- [Events](https://insphero.com/events/): Filter on event focus
- [Careers](https://insphero.com/careers/): At InSphero, we are committed to nourishing our employees' careers and paving the way toward a patient-centered discovery of life-saving drugs for patients worldwide, leveraging the power of 3D Cell Culture technology.
- [3D Cell Culture Tools](https://insphero.com/3d-cell-culture-tools/): For more than a decade, InSphero has developed and optimized technologies for robust and reproducible production, cultivation and assaying of 3D spheroids and organoids. In countless successful collaboration projects with pharmaceutical and biotech partners, our technology has contributed to deep biological insights, better decisions and safer drugs.
- [3D InSight™ Liver Microtissues - Production Schedule](https://insphero.com/production-schedule/): Start your experiment on time with a fast and safe delivery of our3D InSight™ Liver Microtissues from human and preclinical species origin. 
- [Contact Us](https://insphero.com/contact-us/): Talk to Our 3D in vitro Experts and Connect with the InSphero Team
- [Distributors](https://insphero.com/distributors/): By accessing our network of trusted distributors, you can conveniently procure our products, minimize shipping expenses, and save valuable time. Furthermore, our knowledgeable distributors are equipped to provide you with insightful recommendations and guidance, enabling you to make informed purchase decisions.
- [Partners](https://insphero.com/partners/): InSphero partners with leading biotechnological and pharmaceutical companies, academic institutions, and research organizations to advance scientific research and drug development. Through these collaborations, we drive further the development of scalable, reliable, and reproducible 3D cell-based solutions that help researchers yield pragmatic and actionable insights for better and faster decisions.
- [Leadership](https://insphero.com/leadership/): InSphero’s leadership team combines rich scientific and commercial expertise in 3D microtissue engineering, cell-based assays, laboratory automation, and industry-scale production and quality assurance. The strategic management expertise of our Board of Directors and Strategic Advisory Board members complements our leadership scheme.
- [About us](https://insphero.com/about-us/): InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow for more effective, safe therapies to reach the clinic through truly superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to inspire the next generation of breakthrough therapies through customer centricity, commitment to innovation, and the model of excellence.

## Events
- [SBI2 Europe 2026](https://insphero.com/events/sbi2-europe-2026/): Don't miss us at SBI2 Europe 2026 in Boston, Cambridge, UK! 
- [JSOT 2026](https://insphero.com/events/jsot-2026/): Under the theme “Evolving Toxicology - Innovation Emerging from the Confluence of Diverse Fields,” JSOT 2026 will bring together experts from toxicology, life sciences, chemistry, environmental science, AI, data science, and regulatory science to discuss how new methods and collaborations are shaping the future of toxicology.
- [EISG 2026](https://insphero.com/events/eisg-2026/): Connect with our team for the European Islet Study Group Conference, a focused meeting dedicated to advancing the understanding of islet biology and its role in diabetes research.
- [NAMs Industry Mixer at BIO Convention 2026](https://insphero.com/events/nams-industry-mixer-at-bio-convention-2026/): The NAMs Industry Mixer is designed as a focused meeting point for the global MPS and NAMs. At a convention where pharma, biotech, regulators, investors, technology providers, and innovators come together, this event offers a dedicated space to meet peers, continue conversations, and build new relationships beyond the busy exhibition floor.
- [MPS World Summit 2026](https://insphero.com/events/mps-world-summit-2026/): Join us at the MPS World Summit 2026 in Washington, DC, where the global community comes together to advance microphysiological systems and human-relevant models.
- [From Fibrosis Mechanisms to Medicine: 3D Spheroid Models of MASH for Translational Discovery](https://insphero.com/events/webinar-mash-fibrosis-3d-spheroid-models/): In this webinar, on Tuesday, May 12th, 2026, at 11 am EDT, InSphero, together with PharmaNest and Icahn School of Medicine at Mount Sinai, New York,  explored how emerging therapeutic strategies and enabling technologies are shaping the future of MASH treatment, focusing on the continued importance of anti-fibrotic approaches, advanced 3D human in vitro models, and AI-driven digital pathology.
- [AACR 2026](https://insphero.com/events/aacr-2026/): AACR 2026 takes place from April 17-22, and we look forward to connecting with you in San Diego!
- [Keystone Symposia 2026](https://insphero.com/events/keystone-symposia-2026/): Keystone Symposia 2026 takes place March 16th to 19th in Breckenridge, Colorado, bringing the diabetes research community together for “Islet Biology and Diabetes: Beta Cell Compensation, Failure and Recovery.”
- [PBSS 2026](https://insphero.com/events/pbss-2026/): Meet us in Foster City, California, for a dedicated workshop on:
- [SOT 2026](https://insphero.com/events/sot-2026/): The Society of Toxicology (SOT 2026) annual meeting will be hosted in San Diego, California, bringing together toxicology experts and academics from around the world! 
- [Japan MPS Initiative 2026](https://insphero.com/events/japan-mps-initiative-2026/): The Japan MPS Initiative 2026 brings together leading experts in microphysiological systems and organ-on-chip technologies to discuss the latest scientific advances shaping drug discovery, toxicology, and regulatory science.
- [World Organoid Research Day 2026 (WORD+)](https://insphero.com/events/world-organoid-research-day-2026/): WORD+ 2026 is the 4th annual gathering for innovators advancing organoid, organ-on-a-chip, and New Approach Methodologies,  bringing together researchers and industry leaders to share insights on 3D in vitro systems and scalable workflows.
- [SLAS 2026](https://insphero.com/events/slas-2026/): SLAS 2026  is the premier event for laboratory automation, high-throughput screening, and cutting-edge life science technologies. Join InSphero and the Society for Laboratory Automation and Screening in Boston, Massachusetts! 
- [SDDN 2025](https://insphero.com/events/sddn-2025/): We are excited to attend the SDDN 2025 meeting, and connect with researchers advancing innovative approaches in drug discovery. Don't miss the opportunity to discuss the latest advancements in NAMs, and how physiologically relevant 3D in vitro models can strengthen translational confidence in early research.
- [ACT 2025](https://insphero.com/events/act-2025/): Stop by our booth #203 to learn more about how we are shaping the future of drug discovery with our 3D InSight™ Liver Microtissues and in vitro services. ACT 2025 is taking place from Sunday, November 16th to Wednesday, November 19th.  
- [ASCCT 2025](https://insphero.com/events/ascct-2025/): Come join us at the ASCCT 2025! This meeting brings together researchers, regulators, industry, and NGOs to explore the latest in in vitro and computational toxicology and deliberate on regulatory and public health challenges. Whether you’re new to the field or a seasoned professional, this is an unparalled opportunity to learn, share, and drive scientific innovation.  
- [SBI2 2025](https://insphero.com/events/sbi2-2025/): Don't miss us at SBI2 2025 in Boston, Massachusetts! This leading conference in high content imaging and informatics will enhance our understanding on how apply these technologies in new way that drive drug discovery. 
- [NorCal SOT Fall Symposium 2025](https://insphero.com/events/norcal-sot-2025-fall-symposium/): Come join us at the NorCal SOT Fall Symposium 2025! This years theme, "Safety in the Fast Lane: Managing Risk for Emerging Therapeutic Platforms and Technologies" will open the door to exploring everything from the application and utility of liver microtissues to how in vitro models support toxicity studies. 
- [Safety Pharmacology Society 2025](https://insphero.com/events/safety-pharmacology-society-2025/): Don't miss us at Drug Discovery 2025 in Liverpool! This leading conference in drug discovery and innovation will explore new approaches that are decreasing reliance on animal models and icreasing advances in sustainable drug research. 
- [AASLD 2025](https://insphero.com/events/aasld-2025/): Don't miss the chance to connect with us at AASLD 2025, a leading conference for experts, professionals and scientists who are eager to explore the latest breakthroughts in hepatology research and learn more about our 3D in vitro liver disease solutions. 
- [Drug Discovery 2025](https://insphero.com/events/drug-discovery-2025-elrig/): Don't miss us at Drug Discovery 2025 in Liverpool! This leading conference in drug discovery and innovation will explore new approaches that are decreasing reliance on animal models and icreasing advances in sustainable drug research. 
- [PBSS 2025](https://insphero.com/events/pbss-2025/): Join us at PBSS 2025  in Foster City, California. This exciting symposium will bring together experts who will discuss the latest developments in New Approach Methodologies and technologies that seek to phase out animal testing in drug development and discovery. 
- [International Symposium on Microphysiological Systems](https://insphero.com/events/international-symposium-on-microphysiological-systems/): Explore with us at the International Symposium on Microphysiological Systems in Nanjing, China. This event gathers professionals from the organ-on-chip and organoid communities to exchange new developments in research, and drug discoveries. We look forward to connecting with fellow attendees and engaging in insightful discussions!
- [ISSX International Meeting 2025](https://insphero.com/events/issx-international-meeting-2025/): Connect with us at the ISSX International Meeting 2025 in Chicago, Illinois from Sunday, September 21 to Wednesday, September 24. 
- [Discovery on Target 2025](https://insphero.com/events/drug-discovery-on-target-2025/): Join us at Discovery on Target 2025, a premier conference focused on exploring the latest innovations in drug discovery, from NAMs to synthetic biology. This global event brings together scientists and dedicated experts in biotechnology and pharmacology, working to develop modern therapeutics that will change the future. 

## Products
- [Assay-Ready 3D InSight™ Species-Specific Liver Microtissues](https://insphero.com/product/species-specific-liver-microtissues/): 3D InSight™ Species-Specific Liver Microtissues enable direct comparison of hepatotoxicity across human and preclinical species, helping determine whether animal safety signals are relevant to humans and strengthening translational confidence.
- [Gri3D® Hydrogel Microcavity Plates](https://insphero.com/product/gri3d-microplate/): Gri3D® plates are designed to revolutionize 3D cell culture by offering unparalleled precision, scalability, and reproducibility. Each plate features a high-density array of microwells engineered to promote the uniform formation of organoids, enabling researchers to generate physiologically relevant 3D models with ease.
- [Assay-Ready 3D InSight™ Human Liver Microtissues](https://insphero.com/solutions/liver-safety/3d-insight-human-liver-microtissues/): Streamline your research with standardized, ready-to-use, primary cell-based 3D liver models in high-density culture format.
- [Akura™ Immune Flow Organ-on-Chip Platform](https://insphero.com/3d-cell-culture-tools/akura-immune-flow-organ-on-chip-platform/): Bring the Akura™ Immune Flow Organ-on-Chip System into your lab by acquiring our starter kit offering. It’s everything you need to immediately begin investigating complex biological questions in your research:
- [Akura™ Flow Organ-on-Chip Platform](https://insphero.com/3d-cell-culture-tools/akura-flow-organ-on-chip/):  The Akura™ Flow Organ-on-Chip Platform is a multi-organ system engineered to be compatible with spheroids and organoids, including our complete portfolio of 3D InSight™ Microtissues.
- [3D InSight™ Human Islet Microtissues](https://insphero.com/solutions/islet-biology/3d-insight-human-islet-microtissues/): 3D InSight™ Islet Microtissues, produced by reaggregation of dispersed human islet cells, are a standardized alternative to primary human pancreatic islets. They mimic the complex architecture and function of human pancreatic islets while significantly expanding their ex vivo life-span, functional responses and automation compatibility.
- [Akura™ Twin Organ-on-Chip Platform](https://insphero.com/3d-cell-culture-tools/akura-twin-organ-on-chip-platform/): The Akura™ Twin Organ-on-Chip Platform is designed for organ-organ cross-talk in the presence of immune cells with robust handling as well as reliable culturing and analysis.
- [InSphero Incubox™](https://insphero.com/3d-cell-culture-tools/insphero-incubox/): The InSphero Incubox™ is a specially engineered container that creates a high-humidity microclimate inside conventional cell culture incubators and protects your sensitive plates from large humidity drops and fluctuations – the major cause for evaporation effects.
- [Akura™ PLUS Hanging Drop System](https://insphero.com/3d-cell-culture-tools/akura-plus-hanging-drop-system/): The world-famous and unique Akura™ PLUS Hanging Drop System in a 96-well format with automation-compatible top-loading.
- [Akura™ Tilting Stand](https://insphero.com/3d-cell-culture-tools/akura-tilting-stand/): The Akura™ Tilting Stand is a convenient multi-purpose tool for different handling steps with our Akura™ Plate family. It keeps plates at an angle of 30 degrees during cell aggregation improving spheroid/organoid uniformity. It is also used for medium loading and exchange in the Akura™ Flow 384 Plate.
- [Akura™ 96 Spheroid Microplate](https://insphero.com/3d-cell-culture-tools/akura-96-spheroid-microplate/): The Akura™ 96 Spheroid Microplate is the super convenient culturing plate for your daily spheroid/organoid culturing in every lab environment, from manual to automated handling. The plate is designed for lossless spheroid/organoid formation and handling as well as reliable cell culturing and analysis.
- [Akura™ 3D SureKit](https://insphero.com/solutions/liver-safety/akura-3d-surekit/): The Akura™ 3D SureKit provides a validated all-in-one solution to generate and culture organotypic 3D spheroids from primary human hepatocytes.
- [Akura™ 384 Spheroid Microplate](https://insphero.com/3d-cell-culture-tools/akura-384-spheroid-microplate/): The Akura™ 384 Spheroid Microplate is our ultimate spheroid screening plate unifying robust liquid and spheroid handling with automated high-throughput screening applications. The flat bottom and black walls of the InSphero 384-well plate facilitate fluorescent imaging, while the special well design allows medium exchange, dosing, and endpoint determination in the same plate saving time and resources.

## Resources
- [Complex in vitro model developers’ perspective on advanced hepatic in vitro culture methods for predictive drug safety](https://insphero.com/resource/advanced-hepatic-in-vitro-models-perspective/): Maria Vittoria Colombo, Anna Borgström & Bruno G. H. Filippi
- [Studying Fibrosis using 3D InSight Human MASH Microtissues Leveraging ZEISS Lattice Lightsheet 7 for 3D High-Content Analysis](https://insphero.com/resource/zeiss-ins-3d-mash-microtissues-for-fibrosis/)
- [Scalable Whole-Plate Calcium Imaging of Human iPSC-Derived Neural Spheroids for Drug Screening and Neurotoxicity Assessment](https://insphero.com/resource/ipsc-neural-spheroid-calcium-imaging-for-drug-screening/)
- [Non-Destructive Multiplexed Imaging of 3D Liver Microtissues for Multi-Modal DILI Assessment](https://insphero.com/resource/imaging-of-3d-microtissues-for-multi-modal-dili-assessment/)
- [High-throughput single organoid swelling assay for personalized evaluation of CFTR modulators in patient-derived rectal organoids](https://insphero.com/resource/high-throughput-cftr-testing-rectal-organoids/)
- [Influence of 3-dimensional architecture and coculture on in vitro CYP enzyme metabolism and induction: Benchmarking human hepatic spheroids for studies in drug development](https://insphero.com/resource/3d-hepatic-spheroids-cyp-metabolism-induction/): Ann-Kathrin Lenich, Sanja Alsdorf & Stephanie Ruez
- [A Long‐Term Human Liver Spheroid Model for Assessing Silencing and Durability of GalNAc‐Conjugated siRNAs](https://insphero.com/resource/long-term-human-liver-spheroid-model-galnac-sirnas/): Gijs-Jan Scholten, Clara Grundmann, Asa Nordling, Caroline Coskun, Volker Engerlhardt, Lingheswar Sadhasivam, Tomaz Einfalt, Magnus Ingelman-Sundberg & Sander van Riet
- [The dual integrin inhibitor Bexotegrast, indicated for idiopathic pulmonary fibrosis, shows an anti-fibrotic phenotype in human MASH liver spheroids](https://insphero.com/resource/bexotegrast-reduces-fibrosis-human-mash-spheroids/)
- [Evaluation of drug-induced liver injury of Trovafloxacin and Chlorpromazine in human InSight™ 3D MASLD spheroid model](https://insphero.com/resource/evaluation-of-drug-induced-liver-injury-of-trovafloxacin-and-chlorpromazine-in-human-insight-3d-masld-spheroid-model/)
- [Utilizing Cross-species In Vitro Models to Proactively Flag DILI Mechanisms Missed by Traditional Preclinical Testing](https://insphero.com/resource/utilizing-cross-species-in-vitro-models/): This white paper explores how advanced cross-species 3D liver microtissues can improve mechanistic DILI prediction and support proactive preclinical de-risking strategies. Using the case of amcenestrant, a selective estrogen receptor degrader (SERD) associated with cholestatic liver injury in dogs, the study demonstrates how species-specific 3D InSight™ Liver Microtissues successfully identified the underlying mechanism of toxicity that conventional models failed to detect.
- [From Fibrosis Mechanisms to Medicine: 3D Spheroid Models of MASH for Translational Discovery](https://insphero.com/resource/3d-spheroid-models-of-mash/): Watch this on-demand webinar from InSphero, PharmaNest, and Icahn School of Medicine at Mount Sinai exploring why anti-fibrotic therapies remain critical in the GLP-1 era for MASH.
- [3D InSight™ Drug-Induced Gastrointestinal Toxicity Assessment – The human small intestinal organoid assay for drug testing](https://insphero.com/resource/drug-induced-gi-toxicity-organoids/)
- [A Novel Microwell Platform for Organoid Culture Standardization: Intestinal Toxicity Assessment via High-Content Imaging and Phenotypic Analysis](https://insphero.com/resource/microwell-platform-for-organoid-based-intestinal-toxicity/)
- [3D In Vitro Preclinical Models for Drug Discovery in MASH: Validation of Novel Anti-Fibrotics](https://insphero.com/resource/3d-in-vitro-models-for-drug-discovery-in-mash/): Vice President of Liver Disease at InSphero, Francisco Verdeguer, presents new data on the application of 3D in vitro preclinical models for drug discovery in MASH, with a focus on verifying novel anti-fibrotic candidates.
- [Handling instructions for 3D InSight™ Microtissue upon arrival | Ready to use spheroids](https://insphero.com/resource/3d-insight-microtissue-handling-guide/): Our Assay-Ready 3D InSight™ Microtissues are ready-to-use spheroids that provide immediate access to uniform, QC-qualified, pre-aggregated spheroids (one per well), delivered in the Akura™ 96 Spheroid Microplate. Shipped viable and ready for immediate use upon arrival, these physiologically relevant 3D in vitro models eliminate the need for complex in-house model development.
- [Label-Free Quantification of Tumor Spheroid Drug Responses in InSphero ARCTis™ Plates](https://insphero.com/resource/label-free-tumor-drug-testing-with-arctis/): Streamlining the generation of physiologically relevant three-dimensional (3D) cellular models offers significant advantages for biomedical research. Companies support this effort by biobanking primary cells and making them commercially available. One example is the InSphero ARCTis (Always Ready Cryo Tissues) microplates, which contain pre-optimized, cryopreserved human cells that form 3D structures such as spheroids upon thawing. The Spark® Cyto enables real-time monitoring and label-free analysis of these cultures, thereby improving reproducibility and efficiency in high-throughput screening and translational research
- [Always Ready Cryo Tissues (ARCTis™) for Human Tumor - Fast & Convenient Testing of Small Molecules](https://insphero.com/resource/arctis-fast-testing-of-molecules/): This application note demonstrates the use of standardized, cryopreserved 3D human tumor spheroids for robust and predictive small-molecule testing in oncology. Due to their size and shape we also use the term microtissues for them. Using a panel of clinically relevant chemotherapeutic agents, we evaluate compound efficacy across three well-characterized human cancer cell lines, A549 (lung carcinoma), HCT116 (colorectal carcinoma), and T-47D (breast carcinoma), each of which is known to exhibit markedly different therapeutic responses in conventional 2D monolayer cultures compared with 3D tumor models.
- [Automated Generation of Spheroids with CellCare STAR: Standardized 3D Cell Culture Handling](https://insphero.com/resource/automated-3d-spheroid-generation-with-cellcare-star/): The increasing shift toward personalized medicine, coupled with regulatory changes such as the FDA Modernization Act 2.0, is accelerating the transition to 3D cell culture as an alternative to animal models. Automation is essential in supporting this shift by enabling reproducible, scalable, and low-touch workfl ows. The Cell Care STAR now expands its capabilities to include the automated generation and maintenance of 3D cell structures. This Application Note demonstrates how the “Seeding from trough 3D” and “Refresh 3D” work steps enable robust spheroid formation and culture, using the Akura™ 96 Spheroid Microplate (InSphero) as a model system.
- [Standardized Thawing and Sample Preparation of ARCTis™ Cryopreserved Human Tumor Cells Using Akura™ 96 Spheroid Microplates](https://insphero.com/resource/standardized-prep-arctis-cells-akura-plates/): The standardized and automatic handling of cryopreserved biological samples plays an increasingly important role in today’s in vitro testing. This is due to the trend to develop more complex disease models to increase the data quality of pre-clinical studies in terms of biological relevance and, subsequently, their successful translation into medical trials. A major contributor is the development of 3D cell culture methods generating spheroid shaped microtissues. In particular, the dawn of patient-derived models over the last two decades. However, these more sophisticated cell models demand improved handling protocols in comparison to 2D cell culture models. Furthermore, they are either in-house developments of pharmaceutical research labs or supplied by specialized manufacturers. The latter typically provide them as assay-ready consumables to researchers worldwide. This is on the one hand a challenging logistical effort and on the other hand it means that a researcher must start testingdirectly once the material arrives. In this regard, providing such biomaterials cryopreserved is a liberating development.
- [Contrasting Effects of Chronic Glucokinase Activation and Inhibition on Pancreatic Beta-Cell Function](https://insphero.com/resource/nanomaterial-hepatotoxicity-3d-models/): Matthew Lloyd, Natascia Vedovato, Samuel J. Mullan, Alice Elphick, Aerin J. Dumenil, Chantal Rufer, Alexandra C. Title, Burcak Yesildag, Elizabeth Haythorne & Frances M. Ashcroft
- [Microplastic-induced hepatic adverse effects evaluated in advanced quadruple cell human primary models following three weeks of repeated exposure](https://insphero.com/resource/microplastic-exposure-liver-toxicity/): Asha Guraka, Graham Souch, Richard Duff, David Brown, Wolfgang Moritz, Ali Kermanizadeh
- [Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents](https://insphero.com/resource/pfhpa-metabolic-liver-disease-adolescents/): Brittney O Baumert, Ana C Maretti-Mira, Douglas I Walker, Zhenjiang Li, Nikos Stratakis, Hongxu Wang, Yinqi Zhao, Fabian Christoph Fischer, Qiran Jia, Damaskini Valvi, Scott M Bartell, Jiawen Carmen Chen, Thomas Inge, Justin R Ryder, Todd Jenkins, Stephanie Sisley, Stavra Xanthakos, David E Kleiner, Rohit Kohli, Sarah Rock, Sandrah P Eckel, Michele A La Merrill, Max M Aung, Matthew P Salomon, Rob McConnell, Jesse Goodrich, David V Conti, Lucy Golden-Mason, Lida Chatzi
- [Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism](https://insphero.com/resource/cytokine-impaired-alpha-cells-incretin-agonism/): Kristine Henriksen, Chantal Rufer, Alexandra C. Title, Sayro Jawurek, Bolette Hartmann, Jens J. Holst, Filip K. Knop, Burcak Yesildag & Joachim Størling
- [Multiplexing of 3D Cell-Based Assays in Gri3D® Microwell Plates on the Spark® Cyto Multimode Plate Reader and Fluent® Automation Workstation](https://insphero.com/resource/gri3d-plates-spark-reader-fluent-workstation/): Upcyte® hepatocyte spheroids were grown simultaneously in Gri3D (SUN bioscience) and U-bottom ultra-low attachment 96WP to compare ease of use, throughput, assay sensitivity, and scalability for multi-assays. After exposure, drug effects on viability and enzymatic activities were assessed using Promega assays (CellTiterGlo® 3D, CellToxTM Green, LDH-GloTM, and P450-GloTM) and Tecan’s Spark Cyto multi-mode imaging plate reader. Readouts encompassed fluorescence and luminescence intensity measurements, along with imaging. The assays were performed directly on-plate, ensuring the micro tissues remain undisturbed. The Fluent Automation Workstation played a key role in streamlining the workflow, enabling precise and fast cell seeding and media exchanges. Our semi-automated 3D multiplexing approach, combining an innovative microwell plate, compatible cellbased kits, a multimode plate reader, and a liquid handler, provides valuable insights into drug impact on CYP activity and microtissue viability, all within a single experiment. This innovative method advances our understanding of liver spheroid responses to drug exposure and holds promise for larger-scale compound assessments and drug screening using 3D cell cultures.
- [Yokogawa CQ1 Yields High-Content Organoid Imaging with SUN Bioscience Gri3D® Diffractionless Transparent Hydrogel Microwells](https://insphero.com/resource/yokogawa-cq1-high-content-imaging-gri3d/): The primary goal of high-content imaging is to extract more data from biological samples, including, but not limited to, size, shape, number, and intensity. Here, we describe how the use of Yokogawa’s CQ1 high-content imaging system with microlens-enhanced dual Nipkow disk-based spinning disk confocal, combined with SUN Bioscience’s Gri3D® microwell plates, synergize to propel organoid imaging to new heights. This integration empowers scientists to unlock the full potential of organoids in biomedical science.

## Services
- [3D InSight™ Predictive Toxicology Service | 3D <i>In Vitro</i> DILI Testing](https://insphero.com/solutions/liver-safety/predictive-tox-dili/): At InSphero, we offer industry-leading in vitro DILI testing that enables early identification of highly toxic compounds through a physiologically relevant liver model compatible with high-throughput screening. Our 3D InSight™ Liver Microtissues support a broad range of therapeutic modalities, including small molecules and antisense oligonucleotides (ASOs).
- [3D InSight™ Human Beta Cell Proliferation Service - Copy](https://insphero.com/service/type-1-diabetes-platform/): Access our peer-reviewed paper on Type 1 Diabetes:
- [3D InSight™ Translational Toxicology Service | 3D <i>In Vitro</i> Liver Safety Services](https://insphero.com/service/translational-toxicology-service/): Support up to 28-day translational toxicology studies with repeated compound applications.
- [3D InSight™ Human Beta Cell Proliferation Service](https://insphero.com/solutions/islet-biology/beta-cell-proliferation/): Isolated donor islets, traditionally used for the study of human β-cell proliferation, suffer from rapidly deteriorating viability and function ex vivo in their intact form, and once dispersed, their β-cells dedifferentiate and hyperproliferate in culture. In contrast, islet microtissues, produced by reaggregation of gently dispersed human islet cells, represent a uniform, functionally robust and long-lived in vitro islet model that preserve native-like endocrine composition and cell-to-cell interactions critical for physiologically relevant proliferative responses. Uniquely, long-term stable functionality and viability of islet microtissues enables in vitro assessment of changes in β-cell and islet mass in addition to proliferation.
- [3D InSight™ Therapeutic Modality Screening](https://insphero.com/solutions/oncology-and-immunology/therapeutic-modality-screening/): Our 3D InSight™ Oncology platform mimics the physiology and the heterogeneity of the tumor microenvironment and patient-specific characteristics, offering a reliable, accurate in vitro model to test your pipeline of innovative cancer therapeutics. Our 3D InSight™ Oncology platform allows you to get robust, reproducible, and physiologically relevant results for any therapeutic candidate in your discovery program with days to weeks turnaround times.
- [3D InSight™ Immuno-Oncology Screening](https://insphero.com/solutions/oncology-and-immunology/immuno-oncology-screening/): Have you experienced any of the typical challenges in preclinical models for Immuno-Oncology screening?
- [3D InSight™ | 3D <i>In Vitro</i> MASH Screening for Lead Selection](https://insphero.com/solutions/liver-disease/nash-preventive-screening/): Innovative therapies for MASH (Metabolic Dysfunction-associated Steatohepatitis, renamed from NASH) remain a critical unmet medical need. Our MASH Screening Program is designed to support your MASH drug discovery and developmental pipeline in identifying, prioritizing, and de-risking MASH drug candidates early on, using a robust, human-relevant 3D liver MASH model.
- [MASH CALL for Fast and Reliable Identification and Comparison of Drug Candidates](https://insphero.com/service/mash-call-liver-disease/): Join our MASH CALL Initiative and leverage our pioneering approach for drug discovery with valuable insights about the:
- [3D InSight™ | 3D <i>In Vitro</i> MASLD Model for Liver Discovery](https://insphero.com/solutions/liver-disease/nafld-screening/): Leveraging InSphero's market-leading 3D InSight™ MASH model, our 3D In Vitro MASLD model offers equivalent advantages for fatty liver disease research. Experience a high-quality, scalable, and human-relevant 3D cell culture disease model that generates precise insights and facilitates efficient research throughput. Rely on our expertise in creating primary-cell spheroid models and inducing specific disease phenotypes, enabling us to tailor solutions to your needs - fast and efficient for early-stage decision-making.
- [3D InSight™ Investigative Liver Safety Services | 3D <i>In Vitro</i> Liver Safety Services](https://insphero.com/solutions/liver-safety/investigative-tox/): InSphero’s Investigative Toxicology services offer a comprehensive set of solutions to decipher the mechanism of toxicity of a substance. Profiling and hypothesis generation are supported by state-of-the art ‘omics technology, while a comprehensive portfolio of biomarker analysis and classical toxicology mechanistic assays can test a broad set of toxic reactions. InSphero’s team supports you in identifying potential hepatotoxic substances and understanding their mechanisms of toxicity to guide your risk assessment with confidence within weeks.

## Solutions
- [3D InSight™ Tumor Penetration Screening](https://insphero.com/solutions/3d-insight-tumor-penetration-screening/): Our established 3D InSight™ Tumor Penetration Screening platform enables scalable, image-based evaluation of biologics antibody penetration and target localization in human 3D tumor models at single-cell resolution. 
- [3D InSight™ I 3D In Vitro Gastrointestinal Toxicology](https://insphero.com/solutions/3d-insight-gastrointestinal-toxicology/): Drug-Induced Gastrointestinal Toxicity (DIGIT) is a major driver of dose-limiting adverse events, imposing significant patient burden and contributing to treatment discontinuation and clinical attrition. Despite its clinical importance, early predictive assessment of gastrointestinal (GI) risk remains limited.
- [Gri3D®](https://insphero.com/solutions/gri3d/): The Gri3D® Hydrogel Microcavity Plates from SUN Bioscience are joining the InSphero Akura™ family. Expanding our portfolio of advanced 3D cell culture solutions.
- [Liver Safety](https://insphero.com/solutions/liver-safety/): Your proven end-to-end 3D in vitro liver safety solution portfolio - from reliable hazard identification to insights into translational and clinical toxicology
- [Islet Biology](https://insphero.com/solutions/islet-biology/): Your complete end-to-end solution portfolio for the study of islet function, β-cell regeneration and β-cell preservation in physiologically relevant disease models
- [Oncology and Immunology](https://insphero.com/solutions/oncology-and-immunology/): Uncover valuable insights into mechanisms of action and the effect of multiple cell types in Oncology and Immunology by using our physiologically relevant and scalable 3D Human tumor models.
- [Liver Disease](https://insphero.com/solutions/liver-disease/): Imagine the complex nature of liver disease biology condensed into a few plates of assay-ready 3D microtissues. InSphero's 3D in vitro liver disease platform provides you with data and insights that exponentially accelerate your research in MASH (NASH) and MASLD (NAFLD) drug discovery.